Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.48 |
| ▸ | NAMPT | P43490 | 5/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6617521 | 0.84 | MAPK1 (0.72) | MAPK1ESR2NR1H2NAMPTCRBN | |
| SCHEMBL15522791 | 0.83 | MAPK1 (0.70) | MAPK1ESR2NR1H2NAMPTDDB1 | |
| SCHEMBL1396670 | 0.82 | MAPK1 (0.70) | MAPK1ESR2NR1H2NAMPTAHR | |
| SCHEMBL15523943 | 0.82 | MAPK1 (0.70) | MAPK1ESR2NR1H2DDB1CRBN | |
| SCHEMBL19652058 | 0.82 | MAPK1 (0.69) | MAPK1HPGDEPHX2AHR | |
| SCHEMBL15523081 | 0.81 | MAPK1 (0.67) | MAPK1ESR2NR1H2DDB1CRBN | |
| SCHEMBL725393 | 0.81 | MAPK1 (0.67) | MAPK1ESR2NR1H2NAMPTDDB1 | |
| SCHEMBL23874307 | 0.80 | MAPK1 (0.67) | MAPK1ESR2NR1H2AHRDDB1 | |
| SCHEMBL379244 | 0.80 | MAPK1 (0.66) | MAPK1HPGDNAMPTAHRMAPT | |
| SCHEMBL29676965 | 0.79 | MAPK1 (0.64) | MAPK1ESR2NR1H2NAMPTDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782995-B1 | SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2023-11-22 | — | — | EP | disclosed |
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-3097078-B1 | PYRIDINES AND PYRIMIDINES AND USE THEREOF | PURDUE PHARMA LP (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SUZHOU INSTITUTE OF MATERIA MEDICA (CN) | 2022-01-06 | — | — | US | disclosed |
| WO-2021188620-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-04-08 | — | — | US | disclosed |
| EP-3782995-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-09-10 | — | — | US | disclosed |
| WO-2019201291-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | 中国科学院上海药物研究所 | 2019-10-24 | — | — | WO | disclosed |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-03-07 | — | — | US | disclosed |
| WO-2009093269-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC LIMITED (IN) | 2009-07-30 | — | — | WO | disclosed |
| US-20090029965-A1 | Vasopressin V1a Antagonists | FERRING B.V. (NL) | 2009-01-29 | — | — | US | disclosed |
| US-7008938-B2 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | NOKIA CORPORATION (FI) | 2006-03-07 | — | — | US | disclosed |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1481975-A1 | Inhibitors of farnesyl protein transferase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6809092-B2 | 1,3,4,5-TETRAHYDRO-2H-2-BENZAZEPIN-2-YL DERIVATIVES; CYSTEINE PROTEASE INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-26 | — | — | US | disclosed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | disclosed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-6455523-B1 | ADMINISTERING 1,4-BENZODIAZEPINE DERIVATIVE AS ANTITUMOR OR ANTICARCINOGENIC AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6011029-A | BENZODIAZEPINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | MAPK1 901/4885ESR2 4818/4885HPGD 2845/4885 |
| US-20210101891-A1 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | EP300, HDAC11, HDAC1 | MAPK1 1174/4885ESR2 3254/4885HPGD 649/4885 |
| US-20200283439-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | MAPK1 2931/4885ESR2 989/4885HPGD 699/4885 |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | BACH1, BACE1, CMA1 | MAPK1 572/4885ESR2 1814/4885HPGD 1331/4885 |
| US-20220002278-A9 | HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF | EP300, HDAC11, HDAC1 | MAPK1 1174/4885ESR2 3254/4885HPGD 649/4885 |
| US-20050009755-A1 | Benzene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient | BACE1, BACE2, CBS | MAPK1 1583/4885ESR2 1755/4885HPGD 1391/4885 |
| US-20190071443-A1 | TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES | HTR2C, HTR2A, HTR5A | MAPK1 2931/4885ESR2 989/4885HPGD 699/4885 |
| US-20090029965-A1 | Vasopressin V1a Antagonists | AVPR1A, AVPR2, AVPR1B | MAPK1 2062/4885ESR2 647/4885HPGD 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.